Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics.

E Kamma, W Lasisi, C Libner, HS Ng… - Journal of …, 2022 - europepmc.org
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …

Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics

E Kamma, W Lasisi, C Libner, HS Ng… - Journal of …, 2022 - search.proquest.com
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …
[PDF] ubc.ca

[PDF][PDF] Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics

E Kamma, W Lasisi, C Libner, HS Ng, JR Plemel - 2022 - open.library.ubc.ca
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …

Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics.

E Kamma, W Lasisi, C Libner, HS Ng… - Journal of …, 2022 - europepmc.org
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …
[PDF] biomedcentral.com

[PDF][PDF] Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics

E Kamma, W Lasisi, C Libner, HS Ng, JR Plemel - 2022 - jneuroinflammation.biomedcentral …
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …